Monitor for partnership or licensing deals around Plinabulin-ADC combinations given the AACR data, and watch for SEED Therapeutics financing or collaboration updates. The $7.9M cash position provides limited runway for a clinical-stage company with no revenue — a capital raise is likely within 12 months.
Price Chart
Executive Summary
BeyondSpring reported Q1 2026 financial results showing a net loss from continuing operations of $2.4M, improved from a $2.6M loss in Q1 2025, with cash and short-term investments of $7.9M. The key event is the AACR 2026 data positioning Plinabulin as a potential backbone agent for ADC combination therapy and the advancement of SEED's first molecular glue degrader into clinical development, but the company has zero revenue and a limited cash runway.
Key Facts
- Net loss from continuing operations was $2.4M for Q1 2026 vs $2.6M in Q1 2025
- Cash, cash equivalents, and short-term investments were $7.9M as of March 31, 2026
- R&D expenses increased to $1.1M from $0.9M year-over-year
- G&A expenses decreased to $1.1M from $1.7M year-over-year
- Discontinued operations (SEED) net loss was $4.3M vs net income of $3.8M in Q1 2025
- AACR 2026 data showed Plinabulin enhances efficacy and tolerability of ADC-based regimens
- SEED's ST-01156 RBM39 molecular glue degrader advanced into Phase 1 clinical development
- Zero revenue reported for both Q1 2026 and Q1 2025
Financial Impact
Net loss from continuing operations improved by $0.2M year-over-year; cash burn rate suggests ~8-9 months of runway at current spending levels
Risk Factors
- Limited cash runway of $7.9M with no revenue — likely need for near-term financing
- Discontinued operations (SEED) showing increased losses of $4.3M in Q1 2026
- Clinical-stage pipeline with no approved products or near-term commercialization path
- Nasdaq continued listing requirements risk given negative shareholders' equity of $30.4M
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293842 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 8-K | $0.6450 $0.5870 | ▼ −8.99% | ▼ −8.01% | $0.4661 (−27.74%) |
Oct 2, 2026 24d ago | 8-K | $0.7860 $0.6155 | ▲ +21.69% | ▲ +22.11% | $0.4661 (+40.70%) |
Sep 29, 2026 28d ago | 8-K | $0.7733 $0.6923 | ▼ −10.47% | ▼ −12.42% | $0.4661 (−39.73%) |
Sep 29, 2026 28d ago | 424B5 | $0.7733 $0.6923 | ▲ +10.47% | ▲ +12.42% | $0.4661 (+39.73%) |
Sep 18, 2026 5w ago | 8-K | $0.7400 $1.12 | ▼ −51.35% | ▼ −52.37% | $0.4661 (+37.01%) |
Sep 3, 2026 7w ago | DEFA14A | $0.6181 $0.7600 | ▲ +22.96% | ▲ +24.17% | $0.4661 (−24.59%) |
Aug 14, 2026 10w ago | 8-K | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4661 (−34.49%) |
Aug 14, 2026 10w ago | Press Release | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4661 (−34.49%) |
Jun 4, 2026 20w ago | 8-K | $1.71 $1.65 | ▼ −3.51% | ▼ −0.96% | $0.4661 (−72.74%) |
Jun 2, 2026 21w ago | Press Release | $1.70 $1.72 | ▲ +1.18% | ▲ +4.14% | $0.4661 (−72.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers